BCAL TO PRESENT AT NWR VIRTUAL INVESTOR CONFERENCE

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce that it will present at the NWR Virtual Investor Conference.

CEO John Hurrell will present at 11:25am AEST on Monday 2 May 2022.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:
https://us02web.zoom.us/webinar/register/WN_e7cRgSsEQx-nE4qzHIZtCw

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

For more information please visit https://nwrconference.webflow.io/

This ASX announcement has been approved for release by the Board of BCAL.

ENDS

Investor & Media Enquiries

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
+61 451 896 420

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: https://www.bcaldiagnostics.com/